ANI Pharmaceuticals ANIP Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $78.34M+523% | -$18.52M-199% | $18.78M+139% | -$47.9M-12.4% | ||
| $91.42M+35.0% | $67.73M+13.3% | $59.79M+0.2% | $59.65M+26.2% | ||
| $37.93M+29.3% | $29.34M+42.1% | $20.65M+41.5% | $14.6M+39.2% | ||
| $14.24M+165% | -$21.91M-86.7% | -$11.74M+23.0% | -$15.25M+9.0% | ||
| $1.36M+111% | $642K-83.6% | $3.92M-1.0% | $3.96M+57.7% | ||
| $58.53M— | —— | -$3.36M— | —— | ||
| —— | $21.29M+264% | $5.84M-75.3% | $23.63M— | ||
| —— | —— | $7.55M+49.9% | $5.04M— | ||
| $5.02M— | —— | $9.02M+1,030% | $798K— | ||
| -$16M— | —— | $11.99M+7,594% | -$160K+97.9% | ||
| $2.82M— | —— | $0— | $0— | ||
| $1.76M+15.3% | $1.53M+20.3% | $1.27M— | —— | ||
| $185.23M+189% | $64.02M-46.2% | $118.96M— | —— | ||
| $13.84M-14.8% | $16.24M+83.1% | $8.87M-0.1% | $8.88M+247% | ||
| $20.49M+2,757% | $717K-92.6% | $9.64M+27.2% | $7.58M-64.0% | ||
| -$34.32M+91.5% | -$404.72M-2,086% | -$18.51M-17.6% | -$15.74M+85.1% | ||
| $1.16M-28.8% | $1.63M0.0% | $1.63M0.0% | $1.63M+755% | ||
| $12.21M+11.4% | $10.96M+120% | $4.99M+155% | $1.96M+120% | ||
| $0-100% | $292.5M— | $0— | $0-100% | ||
| $0— | $0— | —— | $0-100% | ||
| —— | $269.85M— | —— | -$5.13M-103% | ||
| -$233K+50.4% | -$470K— | —— | $0— | ||
| $140.73M+285% | -$76.23M-145% | $167.89M+422% | -$52.07M— | ||
| $26.93M+10.5% | $24.38M-22.4% | $31.43M+46.3% | $21.48M+121% | ||
| $17.67M-7.3% | $19.06M— | —— | $288K-97.2% | ||
| $1.36M+111% | $642K-83.6% | $3.92M-1.0% | $3.96M+57.7% | ||
| -$32.29M-5,116% | -$619K-143% | $1.43M-64.9% | $4.06M+712% | ||
| $24.44M+297% | $6.16M— | —— | —— | ||
| $5.02M— | —— | $9.02M+1,030% | $798K— | ||
| $10.73M+17.9% | $9.1M— | —— | -$2.4M-137% | ||
| —— | —— | $6.97M+126% | $3.08M— | ||
| —— | $8.38M-32.5% | $12.42M— | —— | ||
| $1.76M+15.3% | $1.53M+20.3% | $1.27M— | —— | ||
| $91.42M+35.0% | $67.73M+13.3% | $59.79M+0.2% | $59.65M— | ||
| $20.49M+2,757% | $717K-92.6% | $9.64M+27.2% | $7.58M-64.0% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $171.39M+259% | $47.78M-56.6% | $110.09M+367% | -$41.23M— | ||
| $171.39M+259% | $47.78M-56.6% | $110.09M+367% | -$41.23M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ANI Pharmaceuticals generate?
- ANI Pharmaceuticals (ANIP) generated $208.6M in operating cash flow over the trailing twelve months.
- What is ANI Pharmaceuticals's free cash flow?
- After $17.4M of capital expenditures, ANI Pharmaceuticals's free cash flow was $191.2M over the trailing twelve months, up 187.0% year over year.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
